bluebird bio Announces FDA Approval of ZYNTEGLO®, the First …
Aug 17, 2022 · bluebird bio has the longest and most robust clinical program in transfusion-dependent beta‑thalassemia (TDT) in the field of gene therapy. The approval of ZYNTEGLO is based on data from bluebird bio’s Phase 3 studies HGB-207 (Northstar-2) and HGB-212 (Northstar-3), and the long-term follow-up study LTF-303.
press releases - bluebird bio, Inc.
Oct 4, 2024 · SOMERVILLE, Mass. --(BUSINESS WIRE)--Mar. 11, 2024-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene autotemcel, also known as lovo-cel) with the state of Michigan .
bluebird bio Announces FDA Approval of LYFGENIA™ …
Dec 8, 2023 · bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events. Severe vaso-occlusive events were eliminated for 94% (30/32) of evaluable patients and all VOEs were eliminated for 88% (28/32) of evaluable patients between 6 and 18 ...
bluebird bio Receives FDA Accelerated Approval for SKYSONA® …
SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease. Management team to host conference call Monday, September 19, at 8:00 a.m. ET.
Bluebird Bio and Resilience Announce Strategic Alliance to …
Alliance designed to foster best in class cell therapy product and manufacturing innovation through risk-sharing and royalty-based model. bluebird to receive $110M upfront, preferred LVV manufacturing access and significantly reduce operational expenses over coming years.
bluebird bio Announces Receipt of Expected Notice from Nasdaq ...
Dec 31, 2023 · The Company is continuing to work expeditiously to complete the filing of the 2023 Form 10-K as promptly as possible. As previously reported, the restatements relate to the identification of embedded leases and the treatment of non-lease components contained in …
bluebird bio Reports First Quarter 2024 Results and Highlights ...
May 9, 2024 · SOMERVILLE, Mass.--(BUSINESS WIRE)--May 9, 2024-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress.
bluebird bio, Inc. Announces Pricing of $125 Million Public …
SOMERVILLE, Mass.--(BUSINESS WIRE)--Dec. 19, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 83,333,333 shares of its common stock at a public offering price of $1.50 per share, before deducting underwriting discounts and commissions. bluebird also granted the ...
investors & media - bluebird bio, Inc.
1 day ago · SOMERVILLE, Mass. --(BUSINESS WIRE)--Nov. 5, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia. Read more
bluebird bio Announces Posting of Briefing Documents for …
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting. June 9 discussion will focus on eli-cel for the treatment of early active cerebral adrenoleukodystrophy in patients without a matched sibling donor and overall safety of lentiviral vector (LVV) gene therapy.
- Some results have been removed